Analyst Actions -- 9/19/2011

 | Sep 19, 2011 | 8:08 AM EDT  | Comments
  • Comment
  • Print Print
  • Print
Stock quotes in this article:

agp

,

adi

,

mu

,

txn

,

AMAT

,

azo

,

bbby

,

jnpr

,

kss

,

nflx

,

wag

Amerigroup estimates, target cut at Goldman

Shares of AGP now seen reaching $47, according to Goldman Sachs. Estimates also reduced, given lower rate and growth trends. Sell rating.

-----

Amerigroup estimates, target cut at UBS

Shares of AGP now seen reaching $49, according to UBS.  Estimates also lowered on higher medical costs.  Maintain Neutral rating.

----- 

Analog Devices upgraded at UBS

ADI was upgraded from Neutral to Buy, UBS said.  $38 price target.  Lead indicators for the industrial segment are bottoming.

----- 

Applied Materials downgraded at Goldman

AMAT was downgraded from Neutral to Sell, Goldman Sachs said. Valuation call, based on a $10.50 price target.

-----

Autozone target increased at Goldman

AZO target was raised to $313, Goldman Sachs said. Company deserves a premium valuation. Sell rating.  

-----

Bed Bath & Beyond target raised at Goldman

Shares of BBBY now seen reaching $62, according to Goldman Sachs. Company's guidance should prove conservative. Neutral rating.

-----

Boardwalk Pipeline upgraded at UBS

BWP was upgraded from Neutral to Buy, UBS said.  $28.50 price target.  Valuation call.

-----

Colgate-Palmolive added to US1 List at BofA Merrill

CL was added to the US1 List, Bank of America Merrill Lynch said.  $100 price target.  Fundamentals on an upswing. 

-----

Continental Resources target increased at Canaccord

CLR price target raised to $92, Canaccord said.  Higher 2H11 oil production outlook.  Maintain Buy rating.

-----

Ensco estimates lowered at Canaccord

CLR estimates lowered through 2012, Canaccord said.  Unplanned downtime for the Ensco 5006.  Maintain $82 price target and Buy rating.

-----

Juniper Networks target cut at Auriga

Shares of JNPR now seen reaching $24, according to Auriga. New product offerings may take longer to ramp. Buy rating.

-----

Kohl's estimates, target reduced at Goldman

Shares of KSS now seen reaching $54, according to Goldman Sachs. Estimates also cut, given new lease accounting Neutral rating.

-----

Lam Research downgraded at Goldman

LRCX was downgraded from Buy to Neutral, Goldman Sachs said. Peak earnings should fall short of expectations. $37 price target.

-----

Linear Technology upgraded at UBS

LLTC was upgraded from Neutral to Buy, UBS said.  $34 price target.  Compelling risk/reward and bottoming fundamentals.

-----

Maxim Integrated upgraded at UBS

MXIM was upgraded from Neutral to Buy, UBS said.  $28 price target.  Strong product cycle to offset macro headwinds. 

-----

Micron Technology upgraded at Goldman

MU was upgraded from Sell to Neutral, Goldman Sachs said. Supply cuts should help the DRAM business. $6.50 price target.

-----

Micron Technology estimates lowered at UBS

MU estimates lowered through 2012, UBS said.  Expect fundamentals to bottom in Q4.  Maintain $14 price target and Buy rating.

-----

Netflix estimates, target cut at Goldman

NFLX estimates were reduced through 2013, Goldman Sachs said. Company lowered its subscriber guidance. Buy rating and new $270 price target.

-----

Oracle target lowered at BMO

ORCL price target lowered to $38, BMO Capital Markets said.  Mixed operating environment.  Maintain Outperform rating.

-----

Oracle target lowered at Think

ORCL price target lowered to $36, ThinkEquity said.  Mixed operating environment.  Maintain Buy rating.

Quanta Services upgraded at FBR

PWR was upgraded from Underperform to Outperform, FBR Capital Markets said. New Keystone pipeline should help drive near-term growth. $24 price target.

-----

Texas Instruments upgraded at UBS

TXN was upgraded from Neutral to Buy, UBS said.  $32 price target.  Potential upside from analog and embedded.

-----

Veeco Instruments estimates, target lowered at UBS

Shares of VECO now seen reaching $43, according to UBS.  Estimates also lowered as near term Korea weakness may continue.  Buy rating.

-----

Walgreens target reduced at Morgan Stanley

WAG target was lowered to $45, Morgan Stanley said. ESRX problem could continue to hang over the stock. Overweight rating.

-----

Warner Chilcott upgraded at Goldman

WCRX was upgraded to Buy, Goldman Sachs said. Valuation call, as the company has an attractive free cash flow yield.

 

 

Columnist Conversations

Using this year's estimate to make a P/E is pretty standard. Basing a multiple on 2015's projected EPS is not ...

BEST IDEAS

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.